Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBC-11 in cancer-induced bone disease
NCT02673060Phase 1Completed
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of MBC-11 in bone metastasis. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 20 weeks, Dose Limiting Toxicity up to 20 weeks and 1 more. Started Jul 2014; status: completed.
02
Drugs
MBC-11
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT02673060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673060.